These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 15246277)
21. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response. Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP; Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532 [TBL] [Abstract][Full Text] [Related]
22. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection. de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973 [TBL] [Abstract][Full Text] [Related]
23. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate. Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298 [TBL] [Abstract][Full Text] [Related]
24. Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus. Balzarini J; Van Laethem K; Daelemans D; Hatse S; Bugatti A; Rusnati M; Igarashi Y; Oki T; Schols D J Virol; 2007 Jan; 81(1):362-73. PubMed ID: 17050611 [TBL] [Abstract][Full Text] [Related]
25. Polyanion inhibitors of human immunodeficiency virus and other viruses. 5. Telomerized anionic surfactants derived from amino acids. Leydet A; Barragan V; Boyer B; Montéro JL; Roque JP; Witvrouw M; Este J; Snoeck R; Andrei G; De Clercq E J Med Chem; 1997 Jan; 40(3):342-9. PubMed ID: 9022800 [TBL] [Abstract][Full Text] [Related]
26. Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120. Férir G; Hänchen A; François KO; Hoorelbeke B; Huskens D; Dettner F; Süssmuth RD; Schols D Virology; 2012 Nov; 433(2):308-19. PubMed ID: 22959895 [TBL] [Abstract][Full Text] [Related]
27. Frequent detection of cell-associated HIV-1 RNA in patients with plasma viral load <50 copies/ml. Kupfer B; Matz B; Däumer MP; Roden F; Rockstroh JK; Qurishi N; Spengler U; Kaiser R J Med Virol; 2007 Oct; 79(10):1440-5. PubMed ID: 17705170 [TBL] [Abstract][Full Text] [Related]
28. The V3 region of gp120 is responsible for anti-HIV-1 activity of heparin sulphate. Jagodzinski PP; Trzeciak WH Acta Biochim Pol; 1998; 45(3):799-804. PubMed ID: 9918507 [TBL] [Abstract][Full Text] [Related]
29. Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication. Auwerx J; Isacsson O; Söderlund J; Balzarini J; Johansson M; Lundberg M Int J Biochem Cell Biol; 2009 Jun; 41(6):1269-75. PubMed ID: 19038358 [TBL] [Abstract][Full Text] [Related]
30. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis? Herbeuval JP; Shearer GM AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946 [TBL] [Abstract][Full Text] [Related]
31. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Neumann T; Hagmann I; Lohrengel S; Heil ML; Derdeyn CA; Kräusslich HG; Dittmar MT Virology; 2005 Mar; 333(2):251-62. PubMed ID: 15721359 [TBL] [Abstract][Full Text] [Related]
32. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262 [TBL] [Abstract][Full Text] [Related]
33. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. Cabrera C; Witvrouw M; Gutiérrez A; Clotet B; Kuipers ME; Swart PJ; Meijer DK; Desmyter J; De Clercq E; Esté JA AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1535-43. PubMed ID: 10580404 [TBL] [Abstract][Full Text] [Related]
34. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Neffe AT; Meyer B Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309 [No Abstract] [Full Text] [Related]
35. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior. Couffin-Hoarau AC; Aubertin AM; Boustta M; Schmidt S; Fehrentz JA; Martinez J; Vert M Biomacromolecules; 2009 Apr; 10(4):865-76. PubMed ID: 19296658 [TBL] [Abstract][Full Text] [Related]
36. Host cyclophilin A mediates HIV-1 attachment to target cells via heparans. Saphire AC; Bobardt MD; Gallay PA EMBO J; 1999 Dec; 18(23):6771-85. PubMed ID: 10581250 [TBL] [Abstract][Full Text] [Related]
37. Anti-HIV-1 activity of low molecular weight sulfated chitooligosaccharides. Artan M; Karadeniz F; Karagozlu MZ; Kim MM; Kim SK Carbohydr Res; 2010 Mar; 345(5):656-62. PubMed ID: 20117763 [TBL] [Abstract][Full Text] [Related]
38. Extension of the polarity-dependent "switch phenomenon" of the gp120 binding domain as a target for antiviral chemotherapy. Graf von Stosch A; Kinzel V; Reed J Biochemistry; 1996 Jan; 35(2):411-7. PubMed ID: 8555210 [TBL] [Abstract][Full Text] [Related]